Type 2 diabetes drugs and weight loss: Calibrate's model starts with pharma and builds out
Calibrate is looking to upend the weight loss industry. And thanks to the drug industry, it’s got a secret weapon – GLP-1 meds.
Over the past few years, next-generation Type 2 diabetes treatments have often chatted up the weight-loss side benefit in TV commercials. Actors and patients in ads have often said things like, “And I may even lose a little weight,” across campaigns for the glucagon-like peptide-1 brands such as Eli Lilly’s Trulicity and Novo Nordisk’s Victoza, Ozempic and Rybelsus.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.